{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:40:59Z","timestamp":1776786059638,"version":"3.51.2"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vinblastine (VBL) is a chemotherapeutic agent commonly used to treat malignant tumors in dogs. Although a maximum tolerated dose of 3.5\u00a0mg\/m2 has been reported, the safety and tolerability of this dose in small dogs remain inadequately characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>Retrospectively evaluate adverse events (AEs) associated with a single IV administration of VBL at a dosage of 2.0\u00a0mg\/m2 in dogs weighing &amp;lt;\u200910\u00a0kg. We hypothesized that AE occurrences in small dogs would be comparable to those reported in phase I studies involving larger breeds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Forty client-owned dogs weighing &amp;lt;\u200910\u00a0kg with malignant tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adverse events after a single IV VBL administration at a dosage of 2.0\u00a0mg\/m2 were retrospectively evaluated in small dogs with malignant tumors. Myelosuppressive and gastrointestinal AEs were graded using VCOG-CTCAE v2.0 criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Neutropenia and thrombocytopenia were observed in 82.5% (33\/40) and 5.0% (2\/40) of dogs, respectively. Grade 3 or 4 neutropenia occurred in 32.5% (13\/40), comprising 15.0% (6\/40) with Grade 3 and 17.5% (7\/40) with Grade 4 events. Inappetence, vomiting, and diarrhea were reported in 7.5% (3\/40), 7.5% (3\/40), and 25.0% (10\/40) of dogs, respectively, and were generally mild. Febrile neutropenia was noted in 5.0% (2\/40) of dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and clinical importance<\/jats:title>\n                    <jats:p>Vinblastine administered at a dosage of 2.0\u00a0mg\/m2 in small dogs with malignant tumors resulted in gastrointestinal toxicity within clinically acceptable limits, but close monitoring for neutropenia is warranted. These findings suggest that dose escalation of VBL, as reported in larger dogs, may not be feasible in smaller dogs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jvimsj\/aalag050","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T12:33:11Z","timestamp":1774873991000},"source":"Crossref","is-referenced-by-count":0,"title":["Adverse events in small dogs treated with a single dose of vinblastine"],"prefix":"10.1093","volume":"40","author":[{"given":"Fukiko","family":"Matsuyama","sequence":"first","affiliation":[{"name":"Japan Small Animal Cancer Center, Japan Small Animal Medical Center , 1-10-4, Higashitokorozawa wada, Tokorozawa-shi, Saitama 359-0023 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Harada","sequence":"additional","affiliation":[{"name":"Japan Small Animal Cancer Center, Japan Small Animal Medical Center , 1-10-4, Higashitokorozawa wada, Tokorozawa-shi, Saitama 359-0023 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanao","family":"Ichimata","sequence":"additional","affiliation":[{"name":"Japan Small Animal Cancer Center, Japan Small Animal Medical Center , 1-10-4, Higashitokorozawa wada, Tokorozawa-shi, Saitama 359-0023 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Fukazawa","sequence":"additional","affiliation":[{"name":"Japan Small Animal Cancer Center, Japan Small Animal Medical Center , 1-10-4, Higashitokorozawa wada, Tokorozawa-shi, Saitama 359-0023 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuzo","family":"Katayama","sequence":"additional","affiliation":[{"name":"Japan Small Animal Cancer Center, Japan Small Animal Medical Center , 1-10-4, Higashitokorozawa wada, Tokorozawa-shi, Saitama 359-0023 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Japan Small Animal Cancer Center, Japan Small Animal Medical Center , 1-10-4, Higashitokorozawa wada, Tokorozawa-shi, Saitama 359-0023 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"2026042110471107200_ref1","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.2460\/javma.1981.179.11.1084","article-title":"Clinical applications of vinca alkaloids","volume":"179","author":"Rosenthal","year":"1981","journal-title":"J Am Vet Med Assoc"},{"key":"2026042110471107200_ref2","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.2460\/javma.1988.193.09.1114","article-title":"Uses of vincristine and vinblastine in dogs and cats","volume":"193","author":"Golden","year":"1988","journal-title":"J Am Vet Med Assoc"},{"key":"2026042110471107200_ref3","first-page":"1499","article-title":"Inhibition of tubulin-microtubule polymerization by drugs of the vinca alkaloid class","volume":"36","author":"Owellen","year":"1976","journal-title":"Cancer Res"},{"key":"2026042110471107200_ref4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1939-1676.1999.tb01468.x","article-title":"Prednisone and vinblastine chemotherapy for canine mast cell tumor-41 cases (1992\u20131997)","volume":"13","author":"Thamm","year":"1999","journal-title":"J Vet Intern Med"},{"key":"2026042110471107200_ref5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1292\/jvms.68.581","article-title":"Outcome and prognostic factors following adjuvant prednisone\/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases","volume":"68","author":"Thamm","year":"2006","journal-title":"J Vet Med Sci"},{"key":"2026042110471107200_ref6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.5326\/0400124","article-title":"Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors","volume":"40","author":"Davies","year":"2004","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026042110471107200_ref7","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1476-5829.2007.00135.x","article-title":"Vinblastine and prednisolone chemotherapy for surgically excised grade III canine cutaneous mast cell tumours","volume":"5","author":"Hayes","year":"2007","journal-title":"Vet Comp Oncol"},{"key":"2026042110471107200_ref8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1746-6148-4-32","article-title":"Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone","volume":"4","author":"Webster","year":"2008","journal-title":"BMC Vet Res"},{"key":"2026042110471107200_ref9","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/j.1939-1676.2011.00796.x","article-title":"Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder","volume":"25","author":"Arnold","year":"2011","journal-title":"J Vet Intern Med"},{"key":"2026042110471107200_ref10","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/vco.12433","article-title":"Response rate to a single dose of vinblastine administered to dogs with treatment-naive multicentric lymphoma","volume":"16","author":"Harding","year":"2018","journal-title":"Vet Comp Oncol"},{"key":"2026042110471107200_ref11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/vms3.42","article-title":"Tolerability of a rapid-escalation vinblastine-prednisolone protocol in dogs with mast cell tumours","volume":"2","author":"Serra Varela","year":"2016","journal-title":"Vet Med Sci"},{"key":"2026042110471107200_ref12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3233\/BLC-150044","article-title":"A nonselective cyclooxygenase inhibitor enhances the activity of vinblastine in a naturally-occurring canine model of invasive urothelial carcinoma","volume":"2","author":"Knapp","year":"2016","journal-title":"Bladder Cancer"},{"key":"2026042110471107200_ref13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/jsap.12500","article-title":"Vinblastine as a second rescue for the treatment of canine multicentric lymphoma in 39 cases (2005 to 2014)","volume":"57","author":"Lenz","year":"2016","journal-title":"J Small Anim Pract"},{"key":"2026042110471107200_ref14","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1111\/j.1939-1676.2008.0196.x","article-title":"Phase I dose escalation of single-agent vinblastine in dogs","volume":"22","author":"Bailey","year":"2008","journal-title":"J Vet Intern Med"},{"key":"2026042110471107200_ref15","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/j.1939-1676.2002.tb02411.x","article-title":"Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma","volume":"16","author":"Garrett","year":"2002","journal-title":"J Vet Intern Med"},{"key":"2026042110471107200_ref16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.2460\/javma.236.6.650","article-title":"Case-control study to evaluate risk factors for the development of sepsis (neutropenia and fever) in dogs receiving chemotherapy","volume":"236","author":"Sorenmo","year":"2010","journal-title":"J Am Vet Med Assoc"},{"key":"2026042110471107200_ref17","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.2460\/ajvr.1994.55.11.1587","article-title":"Comparison of body surface area based and weight-based dosage protocols for doxorubicin administration in dogs","volume":"55","author":"Arrington","year":"1994","journal-title":"Am J Vet Res"},{"key":"2026042110471107200_ref18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.5326\/JAAHA-MS-6545","article-title":"Correlation between body weight and mitoxantrone-associated neutropenia in dogs","volume":"54","author":"Richardson","year":"2018","journal-title":"J Am Anim Hosp Assoc"},{"key":"2026042110471107200_ref19","first-page":"288","article-title":"Unexpected toxicity associated with of body surface area for dosing melphalan in the dog","volume":"48","author":"Page","year":"1988","journal-title":"Cancer Res"},{"key":"2026042110471107200_ref20","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/vco.12622","article-title":"Carboplatin-induced myelosuppression as related to body weight in dogs","volume":"18","author":"Calli","year":"2020","journal-title":"Vet comp. Oncol."},{"key":"2026042110471107200_ref21","doi-asserted-by":"publisher","first-page":"e01052","DOI":"10.1002\/prp2.1052","article-title":"Vinblastine pharmacokinetics in mouse, dog, and human in the context of a physiologically based model incorporating tissue-specific drug binding, transport, and metabolism","volume":"11","author":"Witta","year":"2023","journal-title":"Pharmacol Res Perspect"},{"key":"2026042110471107200_ref22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/vco.12677","article-title":"Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE v2) following investigational therapy in dogs and cats","volume":"19","author":"LeBlanc","year":"2021","journal-title":"Vet Comp Oncol"},{"key":"2026042110471107200_ref23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/vco.13022","article-title":"Prophylactic antimicrobials for prevention of febrile neutropenia in tumour-bearing dogs treated with lomustine","volume":"23","author":"Gumash","year":"2025","journal-title":"Vet Comp Oncol"},{"key":"2026042110471107200_ref24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1365-2125.1993.tb00410.x","article-title":"Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism","volume":"36","author":"Andersson","year":"1993","journal-title":"Br J clin Pharmac"},{"key":"2026042110471107200_ref25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/VMRR.S41005","article-title":"Canine mast cell tumors: diagnosis, treatment, and prognosis","volume":"12","author":"Garrett","year":"2014","journal-title":"Vet Med (Auckl)"},{"key":"2026042110471107200_ref26","first-page":"1335","article-title":"Combination vinblastine and palladia for high-grade and metastatic mast cell tumors in dogs","volume":"62","author":"Todd","year":"2021","journal-title":"Can Vet J"},{"key":"2026042110471107200_ref27","first-page":"1116","article-title":"Pharmacological studies with vinblastine in the dog","volume":"35","author":"Creasey","year":"1975","journal-title":"Cancer Res"},{"key":"2026042110471107200_ref28","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.2460\/javma.24.03.0214","article-title":"Vinblastine\/prednisolone chemotherapy leads to hematological toxicity in dogs with high-grade or metastatic mast cell tumors","volume":"262","author":"Soussa","year":"2024","journal-title":"J Am Vet Med Assoc"},{"key":"2026042110471107200_ref29","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1111\/j.1939-1676.2008.0195.x","article-title":"Efficacy of vinblastine for treatment of canine mast cell tumors","volume":"22","author":"Rassnick","year":"2008","journal-title":"J Vet Intern Med"},{"key":"2026042110471107200_ref30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1476-5829.2007.00147.x","article-title":"Dose-escalating vinblastine for the treatment of canine mast cell tumour","volume":"6","author":"Vickery","year":"2008","journal-title":"Vet Comp Oncol"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/2\/aalag050\/67654963\/aalag050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/2\/aalag050\/67654963\/aalag050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T14:47:20Z","timestamp":1776782840000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/doi\/10.1093\/jvimsj\/aalag050\/8559483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jvimsj\/aalag050","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]},"article-number":"aalag050"}}